Title: Effect of Edaravone on myocardial protection in patients with single valve replacement
Abstract: Objective: To investigate the myocardial protection effect of edaravone(MCI-186) in patients with single valve replacement.Methods: Thirty-two patients with rheumatic heart disease were randomly divided into two groups: MCI-186 group(group M,n=17) received edaravone injection 0.5 mg/kg in venous blood reservoir of cardiopulmonary bypass unit at 10 min before declamping aorta,control group(group C,n=15) did not receive edaravone.Blood samples were taken before skin incision(T1),and at 4 h(T2),8 h(T3),16 h(T4),24 h(T5)after declamping aorta for determination of MDA;at T1,T3,T4 and 72 h(T6) after declamping aorta for determination of CK-MB,Myo,cTnI.Meanwhile,the clinical effectiveness of the two groups was observed. Results: ①After declamping aorta,the levels of CK-MB,Myo,cTnI at T3,T4 in group M were lower than those in group C(P0.01).②The levels of MDA in group M were higher than in group C at all time points after declamping aorta(P0.01).③After declamping aorta,the spontaneous return rate was 60% in group C and 90% in group M.The amount of positive inotropic drugs in group M was less than group C(P0.05). Conclusion: Before reperfusion,MCI-186 can decrease the production of MDA in order to reduce myocardium ischemic reperfusion injury if supplied in time.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot